Scinai Immunotherapeutics Ltd. (SCNI) stock
SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.37−0.01 (-1.40%)
Close on Nov 18, 2026Market cap $1.27MP/E –Yield –
Scinai Immunotherapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Scinai Immunotherapeutics's operating cash flow for the twelve months ending Dec 31, 2021 was -$7.43M. For fiscal 2025 it was -$6.03M. The highest annual figure on record is -$2.90M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.03M | – |
| FY2024 | Dec 31, 2024 | -$6.34M | – |
| FY2023 | Dec 31, 2023 | -$9.38M | – |
| FY2022 | Dec 31, 2022 | -$7.27M | – |
| FY2021 | Dec 31, 2021 | -$7.43M | – |
| FY2020 | Dec 31, 2020 | -$22.56M | – |
| FY2017 | Dec 31, 2017 | -$2.90M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | -$2.88M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.06M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.67M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.11M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.86M | – |
See a number that looks wrong?